Navigation Links
Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance
Date:3/12/2010

-chron">February 2010, we announced the appointment of Felix J. Baker, Ph.D. to our Board of Directors. Dr. Baker is a managing partner of Baker Bros. Advisors, LLC, the manager and advisor to the funds of Baker Brothers Investments, Ardea's largest stockholder.
  • In January 2010, we announced positive results from the second dosing cohort of a completed Phase 2a, proof-of-concept study evaluating the serum urate (sUA) lowering effect, safety and tolerability of combining RDEA594 and allopurinol in gout patients with hyperuricemia (mean sUA level of 10.2 mg/dL). The combination of RDEA594 and allopurinol reduced sUA levels an additional 24 percent compared to allopurinol alone, and resulted in a 100 percent treatment response rate. The combination of RDEA594 and allopurinol in gout patients was well tolerated.
  • Also in January 2010, we announced positive results from the second panel of a Phase 1 drug-drug interaction and pharmacodynamic study of RDEA594 in combination with febuxostat (Uloric®, Takeda Pharmaceutical Company Limited; Adenuric®, Ipsen and Menarini), in healthy volunteers with a mean sUA level of 7.0 mg/dL. The combination of RDEA594 with febuxostat resulted in approximately a 70 to 80 percent mean reduction in sUA levels compared to baseline, reaching mean sUA levels of 1.2 mg/dL. The combination of RDEA594 and febuxostat was well tolerated, with Grade 2 elevations of liver enzymes associated with febuxostat treatment as the only significant laboratory abnormalities.

  • Clinical Development Efforts and Important Upcoming Clinical Development Milestones'/>"/>

    SOURCE Ardea Biosciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
    2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
    3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
    4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
    5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
    6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
    7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
    8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
    9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
    10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
    11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/22/2014)... Aug. 22, 2014  Mark Riccio, director of ... facility, is using the online crowd-funding platform Kickstarter ... imaging to researchers and would-be superheros everywhere: "for ... would YOU do if you had Superman,s X-ray ... and explorers everywhere, from elementary through high school ...
    (Date:8/22/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the ... common stock and warrants at a price of $10,000 ... to deducting underwriting discounts and commissions and offering expenses ... immediately separable and will be issued separately.  The shares ... The NASDAQ Stock Market under the ticker symbol "WGBS" ...
    (Date:8/21/2014)... , Aug. 21, 2014  eRelevance Corporation ... company, announced today that it has completed integration ... solution for Plastic Surgery and Dermatology practices. ... more value to healthcare practices using Nextech," stated ... eRelevance Corporation. "Using information from the EMR we ...
    Breaking Medicine Technology:Cornell's X-ray Imaging Lab Director Uses Kickstarter Campaign to "Democratize" Advanced 3D Imaging 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4eRelevance Corporation Integrates with Nextech Electronic Medical Records 2
    ... WARREN, N.J., Jan. 17, 2012 Roka Bioscience announced ... AOAC Performance Tested Method(SM) certification from the ... was conducted by Silliker, Inc., as part of the ... The Roka Listeria Detection Assay runs on the ...
    ... Positron Corporation (OTCBB: POSC), a leading molecular imaging company ... to announce the acquisition of Manhattan Isotope Technology, LLC ... operations and retained all employees of MIT. In exchange, ... and earn-out consideration of $3,500,000 based on 20 percent ...
    Cached Medicine Technology:Roka Bioscience Awarded AOAC-RI Certification for Roka Listeria Detection Assay 2Positron Finalizes Acquisition of Manhattan Isotope Technology, LLC 2Positron Finalizes Acquisition of Manhattan Isotope Technology, LLC 3
    (Date:8/22/2014)... (PRWEB) August 23, 2014 2014 ... is a professional and in-depth research report on ... Glucose Meter information, including Glucose Meter definition, classification, ... industry overview. This research covers the international market ... industry analysis covering macroeconomic environment & economic situation ...
    (Date:8/22/2014)... Today, Zane Benefits, the #1 Online ... Health Plans. , According to Zane Benefits, employers are ... lower the cost of healthcare without reducing coverage for ... however, can be confusing. , The new guide contains ... main types of ABHPs. It also explains the ...
    (Date:8/22/2014)... NV (PRWEB) August 22, 2014 ... that is written by marketing experts for marketers to ... links has caught the attention of Shane Michaels, prompting ... with Internet marketing in any way knows that content ... in the industry,” reports Michaels. “But even though content ...
    (Date:8/22/2014)... Sacramento, CA (PRWEB) August 22, 2014 Buying ... to an adult who is unsure about available coverage types ... now providing principal life insurance policy pricing to the public ... The use of this tool is free and is expected ... are available to the public throughout the U.S. The system ...
    (Date:8/22/2014)... 22, 2014 Millennium Treatment Group has recently ... a high level of drug use among teenagers. The treatment ... drug addiction and work to minimize drug abuse. , America ... and drug addiction in history. According to the National ... million Americans aged 12 or older—or 9.2 percent of the ...
    Breaking Medicine News(10 mins):Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 2Health News:Glucose Meter Industry Global (Europe, Asia, NA, ROW) Analysis Now Available at ReportsnReports.com 3Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2Health News:Principal Life Insurance Policies Now Quoted for Adults at Insurance Website Online 2Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2
    ... a 27% Increase in Revenues, DALLAS, Oct. 30 ... of Internet-based claims,processing solutions for the healthcare industry, today ... ended September 30, 2008., "We are pleased to ... Don Crosbie, chief executive officer of Claimsnet.,"The increase in ...
    ... Philips,Electronics (NYSE: PHG , AEX: PHI) today ... offer quick relief from seasonal mood-related,problems. With the ... affected,by the increased darkness and experience what is ... blues may include lethargy, lowered mood, problems,sleeping, carbohydrate ...
    ... Mylan Inc. (NYSE: MYL ),today announced that ... company has declared its quarterly dividend of $16.25 per,share ... a liquidation,preference of $1,000.00 per share) payable on Nov. ... of Oct. 31, 2008., Mylan Inc., which provides ...
    ... VIRGINIA BEACH, Va., Oct. 30, 2008 AMERIGROUP,Corporation (NYSE: ... in the,17th Annual Credit Suisse Healthcare Conference on November ... Company,s presentation, which begins Thursday,November 13 at 4:00 p.m. ... http://www.amerigroupcorp.com, on the investors, page. A replay will,be ...
    ... age of disease onset and nerve cell death , , ... genes may be linked to the most common form ... team, from Massachusetts General Hospital-MassGeneral Institute for Neurological Disease ... families with a history of the devastating neurological disorder. ...
    ... Oct. 30 WellPoint,s commercial marketing,team was awarded ... Association,(DMA) for its innovative campaign, "Ecosphere -- Simple ... International ECHO Awards competition is the only international,award ... creativity,strategy and response results., WellPoint,s campaign, conducted ...
    Cached Medicine News:Health News:Claimsnet.com Reports Third Quarter 2008 Results 2Health News:Claimsnet.com Reports Third Quarter 2008 Results 3Health News:Philips Introduces New, Advanced Light Therapy Device to Offer Quick Relief from Winter Blues 2Health News:Philips Introduces New, Advanced Light Therapy Device to Offer Quick Relief from Winter Blues 3Health News:Scientists Spot 4 New Alzheimer's Genes 2Health News:WellPoint Awarded Prestigious International Marketing Award 2
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: